{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-011941","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.765748+00:00","generated_at":"2026-05-15T23:39:43.182285+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BeOne Medicines FY2025 revenue $5.34B (+40% YoY); guides FY2026 $6.2-6.4B","bullets":["Total revenue $5.34B full year (+40% YoY); Q4 revenue $1.5B (+33% YoY).","GAAP net income $286.9M vs loss $644.8M prior year; diluted EPS $2.53 vs loss $6.12.","BRUKINSA global sales $3.9B (+49% YoY); Q4 sales $1.1B (+38%).","Non-GAAP diluted EPS $8.09; Adjusted income from operations $1.1B from $45M prior year.","FY2026 revenue guidance $6.2B-$6.4B; management cites pipeline strength and global leadership."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-011941","json":"https://secwatch.observer/filing/0001628280-26-011941.json","markdown":"https://secwatch.observer/filing/0001628280-26-011941.md","text":"https://secwatch.observer/filing/0001628280-26-011941.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/0001628280-26-011941-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/bgne-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:39:43.182285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}